Movement Alert｜GRAIL, Inc. Intraday Rise 5.05% in Regular Trading, FDA panel support and UBS target hike lift sentiment

Market Focus10-20

On October 20, GRAIL, Inc. rose 5.05% in Regular Trading, trading at $123.76 per share, with turnover of $46.11 million.

The move followed continued positive read-through from Galleri's FDA review and a sharp target price increase from UBS to $175 from $105 while maintaining a Buy rating, reinforcing expectations for regulatory progress and commercialization potential.

Background details show Galleri's premarket approval application received favorable votes from the FDA advisory panel: 10-0 on safety, 6-4 on efficacy, and 7-2 with one abstention on benefit-risk for use in adults aged 50 years or older. Earlier review documents indicated the FDA debate had narrowed toward product positioning and labeling rather than core safety questions, a notable shift for a company developing a blood-based multi-cancer early detection test.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment